|
1
|
Huang WJ, Chen WW and Zhang X:
Huntington's disease: Molecular basis of pathology and status of
current therapeutic approaches. Exp Ther Med. 12:1951–1956. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ghosh R and Tabrizi SJ: Clinical features
of Huntington's disease. Adv Exp Med Biol. 1049:1–28. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McColgan P and Tabrizi SJ: Huntington's
disease: A clinical review. Eur J Neurol. 25:24–34. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burgunder JM: Genetics of Huntington's
disease and related disorders. Drug Discov Today. 19:985–989. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Djoussé L, Knowlton B, Hayden M, Almqvist
EW, Brinkman R, Ross C, Margolis R, Rosenblatt A, Durr A, Dode C,
et al: Interaction of normal and expanded CAG repeat sizes
influences age at onset of Huntington disease. Am J Med Genet A.
119A:279–282. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoss AG, Labadorf A, Latourelle JC, Kartha
VK, Hadzi TC, Gusella JF, MacDonald ME, Chen JF, Akbarian S, Weng
Z, et al: miR-10b-5p expression in Huntington's disease brain
relates to age of onset and the extent of striatal involvement. BMC
Med Genomics. 8:102015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghose J, Sinha M, Das E, Jana NR and
Bhattacharyya NP: Regulation of miR-146a by RelA/NFkB and p53 in
STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease.
PLos One. 6:e238372011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bucha S, Mukhopadhyay D and Bhattacharyya
NP: Regulation of mitochondrial morphology and cell cycle by
microRNA-214 targeting Mitofusin2. Biochem Biophys Res Commun.
465:797–802. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sinha M, Ghose J, Das E and Bhattarcharyya
NP: Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a
targets TBP. Biochem Biophys Res Commun. 396:742–747. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson R, Zuccato C, Belyaev ND, Guest
DJ, Cattaneo E and Buckley NJ: A microRNA-based gene dysregulation
pathway in Huntington's disease. Neurobiol Dis. 29:438–445. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Packer AN, Xing Y, Harper SQ, Jones L and
Davidson BL: The bifunctional microRNA miR-9/miR-9* regulates REST
and CoREST and is downregulated in Huntington's disease. J
Neurosci. 28:14341–14346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Langfelder P, Gao F, Wang N, Howland D,
Kwak S, Vogt TF, Aaronson JS, Rosinski J, Coppola G, Horvath S and
Yang XW: MicroRNA signatures of endogenous Huntingtin CAG repeat
expansion in mice. PLoS One. 13:e01905502018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kartsaki E, Spanaki C, Tzagournissakis M,
Petsakou A, Moschonas N, Macdonald M and Plaitakis A: Late-onset
and typical Huntington disease families from Crete have distinct
genetic origins. Int J Mol Med. 17:335–346. 2006.PubMed/NCBI
|
|
14
|
Miniarikova J, Evers MM and Konstantinova
P: Translation of MicroRNA-based huntingtin-lowering therapies from
preclinical studies to the Clinic. Mol Ther. 26:947–962. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keeler AM, Sapp E, Chase K, Sottosanti E,
Danielson E, Pfister E, Stoica L, DiFiglia M, Aronin N and
Sena-Esteves M: Cellular analysis of silencing the Huntington's
disease gene using AAV9 mediated delivery of artificial micro rna
into the striatum of Q140/Q140 mice. J Huntingtons Dis. 5:239–248.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pfister EL, DiNardo N, Mondo E, Borel F,
Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, et al:
Artificial miRNAs reduce human mutant huntingtin throughout the
striatum in a transgenic sheep model of Huntington's disease. Hum
Gene Ther. Feb 23–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Labadorf A, Hoss AG, Lagomarsino V,
Latourelle JC, Hadzi TC, Bregu J, MacDonald ME, Gusella JF, Chen
JF, Akbarian S, et al: Correction: RNA sequence analysis of human
huntington disease brain reveals an extensive increase in
inflammatory and developmental gene expression. PLoS One.
11:e01602952016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar :
|
|
20
|
Pathan M, Keerthikumar S, Ang CS, Gangoda
L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim
A, et al: FunRich: An open access standalone functional enrichment
and interaction network analysis tool. Proteomics. 15:2597–2601.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lund E, Guttinger S, Calado A, Dahlberg JE
and Kutay U: Nuclear export of microRNA precursors. Science.
303:95–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cha JH: Transcriptional signatures in
Huntington's disease. Prog Neurobiol. 83:228–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Junn E and Mouradian MM: MicroRNAs in
neurodegenerative diseases and their therapeutic potential.
Pharmacol Ther. 133:142–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin J, Cheng Y, Zhang Y, Wood W, Peng Q,
Hutchison E, Mattson MP, Becker KG and Duan W: Interrogation of
brain miRNA and mRNA expression profiles reveals a molecular
regulatory network that is perturbed by mutant huntingtin. J
Neurochem. 123:477–490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park
JE, Park KH, Jung KH, Lee SK, Kim M and Roh JK: Altered microRNA
regulation in Huntington's disease models. Exp Neurol. 227:172–179.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Träger U, Andre R, Lahiri N,
Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C,
Sirinathsinghji E, Kahlon S, Pfister EL, et al: HTT-lowering
reverses Huntington's disease immune dysfunction caused by NFκB
pathway dysregulation. Brain. 137:819–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shrivastava AN, Aperia A, Melki R and
Triller A: Physico-pathologic mechanisms involved in
neurodegeneration: Misfolded protein-plasma membrane interactions.
Neuron. 95:33–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Hagen M, Piebes DGE, de Leeuw WC,
Vuist IM, van Roon-Mom WMC, Moerland PD and Verschure PJ: The
dynamics of early-state transcriptional changes and aggregate
formation in a Huntington's disease cell model. BMC Genomics.
18:3732017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan MM and Raymond LA:
N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in
Huntington's disease. Prog Neurobiol. 81:272–293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moumne L, Betuing S and Caboche J:
Multiple aspects of gene dysregulation Huntington's disease. Front
Neurol. 4:1272013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dunah AW, Jeong H, Griffin A, Kim YM,
Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N and
Krainc D: Sp1 and TAFII130 transcriptional activity disrupted in
early Huntington's disease. Science. 296:2238–2243. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Squitieri F, Cannella M, Sgarbi G,
Maglione V, Falleni A, Lenzi P, Baracca A, Cislaghi G, Saft C,
Ragona G, et al: Severe ultrastructural mitochondrial changes in
lymphoblasts homozygous for Huntington disease mutation. Mech
Ageing Dev. 127:217–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crotti A and Glass CK: The choreography of
neuroinflammation in Huntington's disease. Trends Immunol.
36:364–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Björkqvist M: lmmunomodulation-a
disease-modifying avenue for treatment of Huntington's disease? J
Neurochem. 137:670–672. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Butland SL, Sanders SS, Schmidt ME,
Riechers SP, Lin DT, Martin DD, Vaid K, Graham RK, Singaraja RR,
Wanker EE, et al: The palmitoyl acyltransferase HIP14 shares a high
proportion of interactors with huntingtin: implications for a role
in the pathogenesis of Huntington's disease. Hum Mol Genet.
23:4142–4160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Salem L, Saleh N, Désaméricq G, Youssov K,
Dolbeau G, Cleret L, Bourhis ML, Azulay JP, Krystkowiak P, Verny C,
et al: Insulin-like growth factor-1 but not insulin predicts
cognitive decline in Huntington's disease. PLoS One.
11:e01628902016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hoss AG, Kartha VK, Dong X, Latourelle JC,
Dumitriu A, Hadzi TC, Macdonald ME, Gusella JF, Akbarian S, Chen
JF, et al: MicroRNAs located in the Hox gene clusters are
implicated in Huntington's disease pathogenesis. PLoS Genet.
10:e10041882014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rokavec M, Li H, Jiang L and Hermeking H:
The p53/miR-34 axis in development and disease. J Mol Cell Biol.
6:214–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shapshak P: Molecule of the month: miRNA
and proteins DARPP-32, DRD1, SLC6A3, and CK2. Bioinformation.
9:274–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ooi L and Wood IC: Regulation of gene
expression in the nervous system. Biochem J. 414:327–341. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lloyd TE, Christopher-Stine L,
Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff SK, Pak K,
Casciola-Rosen LA and Mammen AL: Cytosolic 5′-nucleotidase 1A As a
target of circulating autoantibodies in autoimmune diseases.
Arthritis Care Res (Hoboken). 68:66–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cheng PH, Li CL, Chang YF, Tsai SJ, Lai
YY, Chan AW, Chen CM and Yang SH: miR-196a ameliorates phenotypes
of Huntington disease in cell, transgenic mouse, and induced
pluripotent stem cell models. Am J Hum Genet. 93:306–312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fu MH, Li CL, Lin HL, Tsai SJ, Lai YY,
Chang YF, Cheng PH, Chen CM and Yang SH: The potential regulatory
mechanisms of miR-196a in Huntington's disease through
bioinformatic analyses. PLoS One. 10:e01376372015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zou J, Guo P, Lv N and Huang D:
Lipopolysaccharide-induced tumor necrosis factor-α factor enhances
inflammation and is associated with cancer (Review). Mol Med Rep.
12:6399–6404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gerard C, Bruyns C, Marchant A, Abramowicz
D, Vandenabeele P, Delvaux A, Fiers W, Goldman M and Velu T:
Interleukin 10 reduces the release of tumor necrosis factor and
prevents lethality in experimental endotoxemia. J Exp Med.
177:547–550. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nicoletti F, Mancuso G, Cusumano V, Di
Marco R, Zaccone P, Bendtzen K and Teti G: Prevention of
endotoxin-induced lethality in neonatal mice by interleukin-13. Eur
J Immunol. 27:1580–1583. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dobson L, Träger U, Farmer R, Hayardeny L,
Loupe P, Hayden MR and Tabrizi SJ: Laquinimod dampens hyperactive
cytokine production in Huntington's disease patient myeloid cells.
J Neurochem. 137:782–794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee HK, Lee HS and Moody SA: Neural
transcription factors: From embryos to neural stem cells. Mol
Cells. 37:705–712. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Stefani IC, Wright D, Polizzi KM and
Kontoravdi C: The role of ER stress-induced apoptosis in
neurodegeneration. Curr Alzheimer Res. 9:373–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Glowacka WK, Alberts P, Ouchida R, Wang JY
and Rotin D: LAPTM5 protein is a positive regulator of
proinflammatory signaling pathways in macrophages. J Biol Chem.
287:27691–27702. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Raju HB, Tsinoremas NF and Capobianco E:
Emerging putative associations between non-coding RNAs and
protein-coding genes in neuropathic pain: Added value from reusing
microarray data. Front Neurol. 7:1682016. View Article : Google Scholar : PubMed/NCBI
|
